Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.
In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. The Company reported encouraging interim safety and immunogenicity data from the Phase 1/2a study of its personalized DNA-based immunotherapy, EVX-02. The results are summarized below.
“We are thrilled to announce promising interim data from the first eight patients in our Phase 1/2a study of EVX-02. We believe that these results serve as validation of our DNA technology for personalized cancer immunotherapy. All patients demonstrated a specific T-cell immune response induced by the treatment, confirming the potential capabilities of our AI platform technology. And importantly, the treatment appeared to be well tolerated in all patients, with only very mild adverse events (AEs) observed,” said CEO Per Norlén.
Personalized cancer immunotherapy, like EVX-02, is particularly challenging to produce because a new and unique drug is manufactured for each patient.
“This is a tremendous achievement. Our team has successfully completed this complex process, from biopsy, through genome sequencing, a selection of the most promising cancer targets through our AI platform technology, to manufacturing, quality testing, and drug product production and delivery. And they succeeded with every single step for each patient,” says Mr. Norlén.
“The promising EVX-02 data, demonstrating both proof of mechanism and an encouraging safety profile, give us exactly what we need for our upcoming clinical trial of EVX-03 and our next-generation DNA technology.”
Interim results in summary:
- Safety: Treatment appeared to be well tolerated in all patients, with only very mild adverse events (AEs) observed in relation to EVX-02 treatment.
- EVX-02 induced CD4+ and CD8+ specific T-cell responses in all patients, providing proof of mechanism for our DNA-delivery technology, in that the delivered EVX-02-DNA gave rise to immune reactions to its encoded neoantigen peptides.
- The T-cell responses were robust and long-lasting.
A full clinical trial report for the EVX-02 Phase 1 study is expected in the second quarter of 2023.
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. A proprietary and scalable AI technology is used to decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of novel product candidates, including patient-specific cancer immunotherapies. It is located in Hørsholm, Denmark, with 70 employees.
Evaxion Biotech A/S
Chief Executive Officer (CEO)
For more information, please contact
Katrine Hertz Mortensen
VP, Communications and Public Relations
+45 3010 0203
Source: Evaxion Biotech
This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, besides those of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19 and the emergence and prevalence of COVID-19 variants, such as the Delta and Omicron variant and certain related variants such as the Omicron BA.4 and BA.5 variants, risks associated with the invasion of the Ukraine by Russia and other risks and uncertainties affecting the Company’s business operations and financial condition.
Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s Annual Report on Form 20-F filed on March 31, 2022 and the Company’s current and future reports filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Orkuveita Reykjavíkur | Green Bond Auction December 125.12.2023 18:17:17 CET | Press release
Reykjavík Energy (Orkuveita Reykjavíkur; OR) is holding a bond auction on Tuesday, December 12th, 2023. Bonds in the green bond classes OR020934 GB, OR180255 GB and OR161126 GB will be offered for sale. OR161126 GB bears non-indexed interests with an interest payment arrangement and bears 7.0% interest, payable four times a year until the final maturity on November 16, 2026. Previously, bonds with a nominal value of 720 million have been issued in the class. OR020934 GB bears fixed indexed interests and pays equal payments every six months with a final maturity date of September 2, 2034. Previously, bonds with a nominal value of ISK 21,127 million have been issued in the class. OR0180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18, 2055. Previously, bonds with a nominal value of ISK 27,281 million have been issued in the class. Fossar Investment Bank hf. oversees the issuance and sale of the bonds as well as their a
Wereldhave acquires shopping center Polderplein in Hoofddorp, the Netherlands, and enters growth phase of its LifeCentral strategy5.12.2023 17:40:00 CET | Press release
Wereldhave has reached agreement with DELA Vastgoed B.V. (‘DELA’) regarding the acquisition of shopping center Polderplein and its parking garage in Hoofddorp (The Netherlands), with a total gross lettable area of c17,000 m² (excluding parking). The acquisition perfectly fits within Wereldhave’s strategy and acquisition criteria such as location, value creation opportunities and synergies with the recently delivered Full Service Center Vier Meren. Combined, Vier Meren and Polderplein will create one dominant Full Service Center in the best location of the city, with 49,100 m2 lettable area and 105 shops, with Wereldhave as sole owner. The total purchase price amounts to € 74m (€ 82m including transaction costs), reflecting a net initial yield of 7.6%. As the transaction is 70% equity financed, the loan-to-value will improve by c30bps. Matthijs Storm, CEO of Wereldhave commented: “This acquisition marks the start of the growth phase of Wereldhave’s LifeCentral strategy and completes a b
Kvika banki hf.: Result of subordinated bond offering5.12.2023 17:39:25 CET | Press release
Kvika has today concluded an offering of Tier-2 subordinated bonds in a new series, KVIKA 34 1211 T2i. Total demand amounted to ISK 4,820 million. The subordinated bonds were sold at par for an amount of ISK 2,000 million, where total issuance in the series is limited to ISK 4,000 million. The subordinated bonds are index linked and have an annual coupon of 6.25%. The maturity of the bonds is 11 December 2034 and are callable by the issuer at the interest payment date of 11 December 2029 and on every subsequent interest payment date. The subordinated bonds will be issued under Kvika’s EMTN programme and listed on Nasdaq Iceland. For further information please contact Kvika‘s investor relations at firstname.lastname@example.org
Zoom named a Leader in the 2023 Gartner® Magic Quadrant™ for UCaaS, Worldwide5.12.2023 17:31:56 CET | Press release
Zoom Celebrates its Fourth Consecutive Time in the Leaders Quadrant SAN JOSE, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), today announced that analyst firm Gartner has named Zoom a Leader in the 2023 Gartner® Magic Quadrant™ for Unified Communications as a Service (UCaaS), Worldwide for the fourth time in a row. The UCaaS report evaluated 11 companies in the unified communications space, and Zoom has been recognized as a Leader in this space for its UCaaS offerings. Zoom includes enterprise-grade solutions like Zoom Team Chat, Zoom Phone, Zoom Meetings, Zoom Contact Center, and Zoom AI Companion. “We are excited to be named a Leader in the Gartner Magic Quadrant for UCaaS for the fourth consecutive year which we feel is a result of our ongoing commitment to offer an exceptional UCaaS experience," said Graeme Geddes, Chief Growth Officer at Zoom. “As we continue to innovate and evolve our platform, we remain true to solving real customer probl
Innofactor Plc: Share Repurchase 5.12.20235.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 5.12.2023Innofactor Plc: Share Repurchase 5.12.2023In the Helsinki Stock ExchangeTrade date 5.12.2023Bourse trade BuyShare IFA1VAmount 4,600SharesAverage price/ share 1.1465EURTotal cost 5,273.90EURInnofactor Plc now holds a total of 571 129 sharesincluding the shares repurchased on 5.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 email@example.com Attachment Innofactor_5.12_trades